New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2014
09:18 EDTPCYCPharmacyclics price target raised to $166 from $154 at Roth Capital
Roth Capital increased its price target on Pharmacyclics after the FDA approved the company's IMBRUVICA for chronic lymphocytic leukemia. The firm expects sales of the drug to be strong and keeps a Buy rating on the shares.
News For PCYC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2015
10:02 EDTPCYCAbbVie says communication with Johnson & Johnson has been 'very positive'
Subscribe for More Information
09:20 EDTPCYCCelgene patent latest to be challenged by Hayman Capital's Bass
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 110 of U.S. Patent No. 6,045,501 held by Celgene (CELG), according to a USPTO filing. The 501 patent claims methods for delivering a drug, including a teratogenic drug, to a patient while preventing the exposure of a fetus or other contraindicated individuals to the drug. The patent is related to the company's Revlimid drug. BACKGROUND: Previously, the same coalition requested an Inter Partes Review of patents held by Pharmacyclics (PCYC), Acorda Therapeutics (ACOR), Shire (SHPG) and Jazz Pharmaceuticals (JAZZ). On January 7, Reuters reported that Bass planned to take "around 15 pharmaceutical companies with a combined market capitalization of $450B" into an Inter Partes Review for extending patents in questionable ways, citing a presentation made by Bass in Oslo. PRICE ACTION: Shares of Celgene are down 0.5% to $114.92 in pre-market trading.
09:07 EDTPCYCAbbVie says remains on track to complete Pharmacyclics acquisition in Q2
April 22, 2015
14:08 EDTPCYCEarnings Watch: AbbVie's Humira sales will be focus for Q1
Subscribe for More Information
April 20, 2015
14:32 EDTPCYCPharmacyclics patent for Imbruvica challenged by Hayman Capital's Bass
Subscribe for More Information
09:05 EDTPCYCPharmacyclics reports positive data suggesting ibrutinib is an effective option
Ibrutinib data presented yesterday by Pharmacyclics at the American Association for Cancer Research, or AACR, Annual Meeting suggest that ibrutinib may be an effective therapeutic option for pancreatic ductal adenocarcinoma as shown in both a transgenic mouse model and an in-vivo model of patient-derived xenograft mice. These early, pre-clinical data show ibrutinib was associated with potent anti-fibrotic activity and longer survival in the treated mice. PDAC is a type of pancreatic cancer that is typically characterized by a fibro-inflammatory reaction, which makes PDAC a difficult disease to treat with current therapies. These data were also published in the April 15th edition of Cancer Research. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech.
08:47 EDTPCYCPharmacyclics announces positive results from PCYC-1102 study
Pharmacyclics announced that IMBRUVICA follow-up data in treatment-naive, or TN, and relapsed/refractory patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, or CLL and SLL respectively, demonstrated that, with up to 45 months of follow-up, the 94 patients who received IMBRUVICA 420 mg experienced a 91% overall response rate, or ORR, and 14% of all patients achieved a complete response. These data are an analysis of outcomes from the Phase I/IIb study, or PCYC-1102, and the ongoing extension study and were presented in an oral presentation at the American Association of Cancer Research.
April 17, 2015
16:50 EDTPCYCAbbVie extends exchange offer to acquire Pharmacyclics
Subscribe for More Information
April 13, 2015
14:07 EDTPCYCEarnings Watch: Johnson & Johnson shares down slightly since last earnings
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use